Hypophosphatemic rickets

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 19, Issue 6, 2012, Pages 460-467

  Baroncelli, Giampiero I ^a   Toschi, Benedetta ^b   Bertelloni, Silvano ^a  

^a Department of Obstetrics Gynecology and Pediatrics   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

a Klotho; fibroblast growth factor 23; hypophosphatemic rickets; phenotype; treatment

Indexed keywords

ALFACALCIDOL; AUTOTAXIN; CALCITRIOL; DENTIN MATRIX PROTEIN 1; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PHOSPHODIESTERASE I; VITAMIN D DERIVATIVE;

AUTOSOMAL DOMINANT HYPOPHOSPHATEMIC RICKETS; AUTOSOMAL RECESSIVE HYPOPHOSPHATEMIC RICKETS 1; AUTOSOMAL RECESSIVE HYPOPHOSPHATEMIC RICKETS 2; BODY GROWTH; CLCN5 GENE; CLINICAL FEATURE; DISEASE SEVERITY; DMP1 GENE; ENPP1 GENE; FGF23 GENE; GENE; GENE ACTIVATION; GENE LOCUS; GENE MUTATION; HEREDITARY HYPOPHOSPHATEMIC RICKETS WITH HYPERCALCIURIA; HUMAN; HYPOPHOSPHATEMIC RICKETS; IRON DEFICIENCY; METABOLIC REGULATION; NONHUMAN; PHENOTYPE; PHEX GENE; PHOSPHATE METABOLISM; REVIEW; SLC34A3 GENE; TREATMENT INDICATION; TREATMENT OUTCOME; X LINKED HYPOPHOSPHATEMIC RICKETS;

ANIMALS; ANTIBODIES, NEUTRALIZING; DNA MUTATIONAL ANALYSIS; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; IRON; MALE; MICE; MUTATION; PHOSPHATES; PROGNOSIS; VITAMIN D;

EID: 84869875826     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e328358be97     Document Type: Review

References (46)

1. Albright F, Butler AM, Bloomberg E. Rickets resistant to vitamin D therapy. Am J Dis Child 1937; 54:529-547.
2. Hori M, Shimizu Y, Fukumoto S. Minireview: fibroblast growth factor 23 in phosphate homeostasis and bone metabolism. Endocrinology 2011; 152:4-10.
3. Fukumoto S, Shimizu Y. Fibroblast growth factor 23 as a phosphotropic hormone and beyond. J Bone Miner Metab 2011; 29:507-514.
4. Juppner H. Phosphate and FGF-23. Kidney Int 2011; 79 (Suppl 121): 1-4.
5. Martin A, David V, Quarles LD. Regulation and function of the FGF23/Klotho endocrine pathways. Physiol Rev 2012; 92:131-155.
6. Opsahl Vital S, Gaucher C, Bardet C, et al. Tooth dentin defects reflect genetic disorders affecting bone mineralization. Bone 2012; 50:989-997.
7. Veilleux LN, Cheung M, Ben Amor M, Rauch F. Abnormalities in muscle density and muscle function in hypophosphatemic rickets. J Clin Endocrinol Metab 2012; 97:E1492-E1498.
8. Alon US. Fibroblast growth factor (FGF)23: a new hormone. Eur J Pediatr2011;170:545-554.
9. Gattineni J, Baum M. Genetic disorders of phosphate regulation. Pediatr Nephrol 2012; 27:1477-1487.
10. Saito T, Shimizu Y, Hori M, et al. A patient with hypophosphatemic rickets and ossification of posterior longitudinal ligament caused by a novel homozygous mutation in ENPP1 gene. Bone 2011; 49:913-916.
11. Carpenter TO. The expanding family of hypophosphatemic syndromes. J Bone Miner Metab 2012; 30:1-9.
12. Mehta P, Mitchell A, Tysoe C, et al. Novel compound heterozygous mutations in ENPP1 cause hypophosphataemic rickets with anterior spinal ligament ossification. Rheumatology (Oxford) 2012; 51:1919-1921.
13. Kinoshita Y, Saito T, Shimizu Y, et al.Mutational analysis of patients with FGF23-related hypophosphatemic rickets. Eur J Endocrinol 2012; 167:165-172.
14. Beck-Nielsen SS, Brixen K, Gram J, Brusgaard K. Mutational analysis of PHEX, FGF23, DMP1, SLC34A3 and CLCN5 in patients with hypophosphatemic rickets. J Hum Gen 2012; 57:453-458.
15. Yu Y, Sanderson SR, Reyes M, et al. Novel NaPi-IIc mutations causing HHRH and idiopathic hypercalciuria in several unrelated families: long-term follow-up in one kindred. Bone 2012; 50:1100-1106.
16. Haito-Sugino S, Ito M, Ohi A, et al. Processing and stability of type IIc sodiumdependent phosphate cotransporter mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria. Am J Physiol Cell Physiol 2012; 302:C1316-1330.
17. Hasani-Ranjbar S, Amoli MM, Ebrahim-Habibi A, et al. SLC34A3 intronic deletion in a new kindred with hereditary hypophosphatemic rickets with hypercalciuria. J Clin Res Pediatr Endocrinol 2012; 4:89-93.
18. Claverie-Mart́n F, Ramos-Trujillo E, Garća-Nieto V. Dent's disease: clinical features and molecular basis. Pediatr Nephrol 2011; 26:693-704.
19. Bacchetta J, Salusky IB. Evaluation of hypophosphatemia: lessons from patients with genetic disorders. Am J Kidney Dis 2012; 59:152-159.
20. Brownstein CA, Adler F, Nelson-Williams C, et al. A translocation causing increased a-Klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci USA 2008; 105:3455-3460.
21. Shalhoub V, Ward SC, Sun B, et al. Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3. E1 cell proliferation and inhibit mineralization. Calcif Tissue Int 2011; 89:140-150.
22. Perwad F, Portale AA. Vitamin D metabolism in the kidney: regulation by phosphorus and fibroblast growth factor 23. Mol Cell Endocrinol 2011; 347:17-24.
23. Quarles LD. 'Dem bones' are made for more than walking. Nat Med 2011; 17:428-430.
24. John GB, Cheng CY, Kuro-O M. Role of Klotho in aging, phosphate metabolism, and CKD. Am J Kidney Dis 2011; 58:127-134.
25. Bergwitz C, Jü ppner H. FGF23 and syndromes of abnormal renal phosphate handling. Adv Exp Med Biol 2012; 728:41-64.
26. Prié D, Friedlander G. Genetic disorders of renal phosphate transport. N Engl J Med 2010; 362:2399-2409.
27. Kuro-O M. Phosphate and klotho. Kidney Int 2011; 79(Suppl 121):S20-23.
28. Razzaque MS. FGF23, klotho and vitamin D interactions: what have we learned from in vivo mouse genetics studies? Adv Exp Med Biol 2012; 728:84-91.
29. David V, Martin A, Hedge AM, et al. ASARM peptides: PHEX-dependent and-independent regulation of serum phosphate. Am J Physiol Renal Physiol 2011; 300:F783-F791.
30. Rowe PSN. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway. Crit Rev Eukaryot Gene Expr 2012; 22:61-86.
31. Wang X, Wang S, Li C, et al. Inactivation of a novel FGF23 regulator, FAM20C, leads to hypophosphatemic rickets in mice. PLoS Genet 2012; 8:e1002708.
32. Farrow EG, Yub X, Summers LJ, et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA 2011; 108:E1146-1155.
33. Imel EA, Peacock M, Gray AK, et al. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 2011; 96:3541-3549.
34. Braithwaite V, Jarjou LMA, Goldberg GR, et al. Follow-up study of Gambian children with rickets-like bone deformities and elevated plasma FGF23: possible aetiological factors. Bone 2012; 50:218-225.
35. Braithwaite V, Jarjou LM, Goldberg GR, Prentice A. Iron status and fibroblast growth factor-23 in Gambian children. Bone 2012; 50:1351-1356.
36. Igaki JM, Yamada M, Yamazaki Y, et al. High iFGF23 level despite hypophosphatemia is one of theclinical indicators to make diagnosis of XLH. Endocr J 2011; 58:647-655.
37. Imel EA, DiMeglio LA, Hui SL, et al. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab 2010; 95:1846-1850.
38. Tournis S, Georgoulas T, Zafeiris C, et al. Tertiary hyperparathyroidism in a patient with X-linked hypophosphatemic rickets. J Musculoskelet Neuronal Interact 2011; 11:266-269.
39. Morey M, Castro-Feijó o L, Barreiro J, et al. Genetic diagnosis of X-linked dominant hypophosphatemic rickets in a cohort study: tubular reabsorption of phosphate and 1,25(OH)2D serum levels are associated with PHEX mutation type. BMC Med Genet 2011; 12:116.
40. Carpenter TO, Imel EA, Holm IA, et al. A clinician's guide to X-linked hypophosphatemia. J Bone Min Res 2011; 26:1381-1388.
41. Quinlan C, Guegan K, Offiah A, et al. Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment. Pediatr Nephrol 2012; 27:581-588.
42. Zivicnjak M, Schnabel D, Staude H, et al. Three-year growth hormone treatment in short children with X-linked hypophosphatemic rickets: effects on linear growth and body disproportion. J Clin Endocrinol Metab 2011; 96:E2097-E2105.
43. Prasad AN, Holla RG. Growth hormone treatment in a child with X-linked hypophosphataemic rickets. MJAFI 2011; 67:359-361.
44. Liu ES, Carpenter TO, Gundberg CM, et al. Calcitonin administration in X-linked hypophosphatemia. N Engl J Med 2011; 364:1678-1680.
45. Aono Y, Hasegawa H, Yamazaki Y, et al. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp Mice. J Bone Miner Res 2011; 26:803-810.
46. Shimada T, Fukumoto S. FGF23 as a novel therapeutic target. Adv Exp Med Biol 2012; 728:158-170.